IN2012DE00262A - - Google Patents

Download PDF

Info

Publication number
IN2012DE00262A
IN2012DE00262A IN262DE2012A IN2012DE00262A IN 2012DE00262 A IN2012DE00262 A IN 2012DE00262A IN 262DE2012 A IN262DE2012 A IN 262DE2012A IN 2012DE00262 A IN2012DE00262 A IN 2012DE00262A
Authority
IN
India
Prior art keywords
compounds
carboxylates
preparing
treatment
metabolic disorders
Prior art date
Application number
Other languages
English (en)
Inventor
Atul Goel
Gaurav Taneja
Neha Rahuja
Arun Kumar Rawat
Natasha Jaiswal
Akhilesh Kumar Tamrakar
Arvind Kumar Srivastava
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Priority to EP13708242.6A priority Critical patent/EP2809654B1/en
Priority to IN262DE2012 priority patent/IN2012DE00262A/en
Priority to US14/376,097 priority patent/US9096539B2/en
Priority to PCT/IN2013/000056 priority patent/WO2013114403A1/en
Publication of IN2012DE00262A publication Critical patent/IN2012DE00262A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN262DE2012 2012-01-31 2013-01-29 IN2012DE00262A (ru)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP13708242.6A EP2809654B1 (en) 2012-01-31 2013-01-29 Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders
IN262DE2012 IN2012DE00262A (ru) 2012-01-31 2013-01-29
US14/376,097 US9096539B2 (en) 2012-01-31 2013-01-29 Substituted 4,5-dihydro-2H-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders
PCT/IN2013/000056 WO2013114403A1 (en) 2012-01-31 2013-01-29 Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN262DE2012 IN2012DE00262A (ru) 2012-01-31 2013-01-29

Publications (1)

Publication Number Publication Date
IN2012DE00262A true IN2012DE00262A (ru) 2015-07-10

Family

ID=47843357

Family Applications (1)

Application Number Title Priority Date Filing Date
IN262DE2012 IN2012DE00262A (ru) 2012-01-31 2013-01-29

Country Status (4)

Country Link
US (1) US9096539B2 (ru)
EP (1) EP2809654B1 (ru)
IN (1) IN2012DE00262A (ru)
WO (1) WO2013114403A1 (ru)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101076703A (zh) * 2004-10-13 2007-11-21 Ptc医疗公司 用于无义抑制的化合物及其使用方法
WO2006080406A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. 三環性化合物
CL2008000793A1 (es) 2007-03-23 2008-05-30 Xenon Pharmaceuticals Inc Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.

Also Published As

Publication number Publication date
US9096539B2 (en) 2015-08-04
WO2013114403A1 (en) 2013-08-08
EP2809654A1 (en) 2014-12-10
EP2809654B1 (en) 2017-04-12
WO2013114403A8 (en) 2013-10-03
US20150005357A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
MY169980A (en) Bisaryl-linked aryltriazolones and their use
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
MY170713A (en) Treatment protocol of diabetes type 2
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
MX2011008262A (es) Espiroamidas sustituidas como moduladores de b1r:.
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
PH12014501963A1 (en) Inhibitors of beta-secretase
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
PH12015500746A1 (en) Benzamides
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
MX2014007364A (es) Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas.
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
UA103197C2 (ru) Применение нифуртимокса для лечения болезней, вызванных трихомонадами
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.